Precision Solutions

• 
  Mammalian Cell Protein Expression Services — HEK293 & CHO Platform

  AtaGenix provides mammalian cell protein expression services (HEK293/CHO-S transient, CHO-K1/DG44 stable) for basic research, drug development, and diagnostic reagent production. 5,000+ projects delivered with native glycosylation, endotoxin <0.1 EU/mL, scalable from mL to 200 L+. ISO 9001 & ISO 13485 certified.

• 
  XtenCHO™ High-Density Transient Transfection Expression System

  XtenCHO™ is AtaGenix's proprietary high-density transient CHO expression system, achieving 200–400 mg/L typical yield (up to 1 g/L for select antibodies). Extended cell viability (10–14 days), cost-optimized reagents, and simplified workflows make it ideal for high-throughput antibody screening and scalable protein production. End-to-end from gene synthesis to bioreactor scale-up in 6–9 weeks.

• 
  Prokaryotic Protein Expression Services — E. coli 3H Platform

  AtaGenix's 3H E. coli expression platform delivers >95% success rate with optimized pET/pGEX vectors, specialized host strains (T7E, C41, Arctic), and complete QC pipeline (purity ≥85%, endotoxin <0.1 EU/mL). Supports antigens, enzymes, fusion proteins, and antibody immunogens from mg to gram scale. Reagents cited in three Nature Communications papers. ISO 9001 & ISO 13485 certified.

• 
  ENO1 Monoclonal Antibody Development for Cervical Cancer Glycolysis Targeting

  AtaGenix expressed ENO1 protein via Sf9/BEVS and screened five hybridoma cell lines producing anti-ENO1 monoclonal antibodies. ENO1mAbs blocked plasminogen activation, inhibited glycolysis, and suppressed cervical cancer cell (SiHa/HeLa) invasion, proliferation, and colony formation — establishing the basis for FA-SS-PLGA nanoparticle-mediated targeted therapy. Published in American Journal of Cancer Research.